| All Releases |
|---|
 |
EpiCept Establishes At-the-Market Public Stock Offering Program
Feb 5, 2010
|
12.3 KB
|
| |
TARRYTOWN, N.Y., Feb 05, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm: EPCT) announced
today that it has established an at-the-market program through which it
may sell, from time to time and at its sole discretion, shares of its
common stock having an aggregate offering price...
|
|
|
EpiCept Regains Nasdaq Compliance
Feb 3, 2010
|
10.8 KB
|
| |
TARRYTOWN, N.Y., Feb 03, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced that Nasdaq notified the Company that it has regained
compliance with the minimum bid price requirement in Listing Rule
5550(a)(2) and met the requirements of the Nasdaq List...
|
|
|
EpiCept to Present at 12th Annual BIO CEO & Investor Conference
Feb 2, 2010
|
11.3 KB
|
| |
TARRYTOWN, N.Y., Feb 02, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nasdaq Stockholm Exchanges: EPCT)
today announced that Jack Talley, President and CEO, will be presenting
at the 12th Annual BIO CEO & Investor Conference on Monday,
February 8, 2010 at 2:00 p.m. Eastern time. The conferenc...
|
|
|
EpiCept Receives Orphan Drug Designation for EpiCept(TM) NP-1 in U.S.
Jan 27, 2010
|
12.3 KB
|
| |
TARRYTOWN, N.Y., Jan 27, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
announced today that EpiCeptTM NP-1 has been granted orphan
drug designation by the U.S. Food and Drug Administration (FDA) for the
treatment of post-herpetic neuralgia (PHN). NP-1 is a pres...
|
|
|
EpiCept Announces Ceplene(R) Included in Swedish AML Medical Guidelines
Jan 26, 2010
|
12.6 KB
|
| |
TARRYTOWN, N.Y., Jan 26, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Stockholm Exchange: EPCT) announced
today that the Swedish AML Group which comprises the leading hematology
experts in Sweden has included Ceplene(R) (histamine
dihydrochloride) in its Guidelines entitled "National Guidelin...
|
|
|
EpiCept Announces Reverse Split of Common Stock
Jan 14, 2010
|
12.6 KB
|
| |
TARRYTOWN, N.Y., Jan 14, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
(the "Company") announced today that a previously authorized 1-for-3
reverse stock split of its common stock has been consummated and will be
in effect as follows:
Nasdaq Capital MarketThe ...
|
|
|
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Jan 11, 2010
|
12.8 KB
|
| |
TARRYTOWN, N.Y., Jan 11, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that it has entered into an exclusive commercialization agreement
for Ceplene(R) (histamine dihydrochloride) with Meda AB, (OMX
Nordic Exchange: MEDA-A-ST) a leading international spec...
|
|
|
EpiCept Announces Results of Special Meeting of Stockholders
Jan 8, 2010
|
11.6 KB
|
| |
TARRYTOWN, N.Y., Jan 08, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today the results of its Special Meeting of Stockholders held on January
7, 2010 in Tarrytown, NY.
Holders of an aggregate of 132,094,079 shares of the Company's common
stock were entitled ...
|
|
|
EpiCept to Present at OneMedPlace Finance Forum
Jan 7, 2010
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Jan 07, 2010 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that EpiCept President and CEO Jack Talley will make a corporate
presentation at the OneMedPlace Finance Forum on Wednesday, January 13
at 2:30 p.m. PST. The Conference is being held f...
|
|
|
EpiCept Provides Clinical and Business Update on Ceplene Program
Dec 15, 2009
|
14.4 KB
|
| |
TARRYTOWN, N.Y., Dec 15, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
provided an update on new clinical developments and other initiatives
related to Ceplene(R) (histamine dihydrochloride), the Company's therapy
approved in the European Union for the remission ma...
|
|
|
EpiCept to Present at Lippert/Heilshorn & Associates Life Sciences Virtual Conference
Dec 11, 2009
|
12.2 KB
|
| |
TARRYTOWN, N.Y., Dec 11, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announces
that EpiCept President and CEO Jack Talley will make a corporate
presentation at the Lippert/Heilshorn & Associates Life Sciences Virtual
Conference. The webcast presentation will be availab...
|
|
|
EpiCept Corporation Reports Third Quarter Results, Provides Business Update
Nov 10, 2009
|
29.2 KB
|
| |
TARRYTOWN, N.Y., Nov 10, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced operating and financial results for the three and nine months
ended September 30, 2009, and provided an update on Ceplene(R) and several
of the Company's key product candidates. Ceplen...
|
|
|
EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application for Review
Nov 9, 2009
|
12.0 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Health Canada has accepted for review the Company's New
Drug Submission (NDS) for Ceplene(R) (histamine
dihydrochloride) for the remission maintenance of acute myeloid leukemia
...
|
|
|
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Nov 6, 2009
|
11.7 KB
|
| |
TARRYTOWN, N.Y., Nov 06, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it has appointed Bernard R. Tyrrell as the Company's
Senior Vice President, Sales and Marketing, a newly created position.
Mr. Tyrrell joins EpiCept with a wealth of experience in...
|
|
|
EpiCept to Report Third Quarter 2009 Operating and Financial Results on November 10, 2009
Nov 5, 2009
|
11.6 KB
|
| |
TARRYTOWN, N.Y., Nov 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss third quarter
2009 operating and financial results on Tuesday, November 10, 2009 at
9:00 a.m. EST. The call will follow the release of th...
|
|
|
Nasdaq Panel Grants EpiCept's Request for Continued Listing
Nov 3, 2009
|
11.1 KB
|
| |
TARRYTOWN, N.Y., Nov 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that a Nasdaq Hearings Panel has granted the Company's request
for continued listing on The Nasdaq Stock Market. The Company's
continued listing is subject to the Company's satisfactio...
|
|
|
EpiCept to Present at BIO-Europe 2009
Nov 2, 2009
|
11.1 KB
|
| |
TARRYTOWN, N.Y., Nov 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
BIO-Europe 2009 Conference on November 3, 2009 at 2:15 p.m. local time
at the Hilton Vienna Danube Hotel in Vienna, Austr...
|
|
|
New Data Supports Pharmacoeconomic Benefits of Ceplene(R)
Oct 26, 2009
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Oct 26, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announces the
release of new findings demonstrating the pharmacoeconomic benefits of
Ceplene(R) (histamine dihydrochloride) for the remission
maintenance of Acute Myeloid Leukemia (AML) patients in fi...
|
|
|
EpiCept's Ceplene(R) Highlighted in Two 2008 European Union Drug Approval Reports
Sep 3, 2009
|
11.7 KB
|
| |
TARRYTOWN, N.Y., Sep 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Ceplene(R) (histamine dihydrochloride) has been
highlighted in two separate reports issued recently reviewing 2008 drug
approvals in the European Union. One report, issued by the ...
|
|
|
EpiCept Corporation to Present at the Rodman & Renshaw Healthcare Conference
Sep 2, 2009
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Sep 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
Rodman & Renshaw 11th Annual Healthcare Conference. The
presentation is scheduled for September 9, 2009 at 3:15 pm Easter...
|
|
|
